Eledon reports Q3 2026 results, Phase 3 LEGACY trial on track for year-end start
Eledon said its global Phase 3 kidney transplant trial of tegoprubart remains set to begin in the fourth quarter, alongside new islet cell IND clearance and Fast Track status.
SEC filing